LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

Search

Relay Therapeutics Inc

Abrir

SetorSaúde

3.05 1.67

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.06

Máximo

3.25

Indicadores-chave

By Trading Economics

Rendimento

-1.1M

-77M

Vendas

7.7M

7.7M

EPS

-0.45

Margem de lucro

-1,003.581

Funcionários

261

EBITDA

-1.2M

-85M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+385.33% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-95M

554M

Abertura anterior

1.38

Fecho anterior

3.05

Sentimento de Notícias

By Acuity

50%

50%

170 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Relay Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de mai. de 2025, 23:48 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

11 de mai. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

11 de mai. de 2025, 23:45 UTC

Conversa de Mercado

Oil Rises Amid Improved Market Mood -- Market Talk

11 de mai. de 2025, 23:38 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Aristocrat Has Significant Firepower for M&A -- Market Talk

11 de mai. de 2025, 23:36 UTC

Conversa de Mercado

Global Markets Uncertain About US-China Trade News -- Market Talk

11 de mai. de 2025, 23:35 UTC

Conversa de Mercado

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

11 de mai. de 2025, 23:33 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

11 de mai. de 2025, 23:32 UTC

Principais Notícias

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

11 de mai. de 2025, 22:44 UTC

Conversa de Mercado

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

11 de mai. de 2025, 22:33 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

11 de mai. de 2025, 20:19 UTC

Principais Notícias

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

11 de mai. de 2025, 16:00 UTC

Principais Notícias

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

11 de mai. de 2025, 11:00 UTC

Principais Notícias

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

11 de mai. de 2025, 08:00 UTC

Principais Notícias

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

11 de mai. de 2025, 01:00 UTC

Principais Notícias

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

11 de mai. de 2025, 01:00 UTC

Principais Notícias

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

10 de mai. de 2025, 21:54 UTC

Principais Notícias

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10 de mai. de 2025, 17:12 UTC

Principais Notícias

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10 de mai. de 2025, 15:41 UTC

Principais Notícias

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

10 de mai. de 2025, 12:00 UTC

Principais Notícias

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10 de mai. de 2025, 09:30 UTC

Principais Notícias

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

10 de mai. de 2025, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

10 de mai. de 2025, 03:52 UTC

Principais Notícias

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9 de mai. de 2025, 23:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9 de mai. de 2025, 22:06 UTC

Conversa de Mercado

Arm Holdings Remains a Strong Growth Story -- Market Talk

9 de mai. de 2025, 21:37 UTC

Principais Notícias

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9 de mai. de 2025, 21:10 UTC

Principais Notícias

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

9 de mai. de 2025, 20:42 UTC

Principais Notícias

Stocks Get a Break From Trade Chaos -- WSJ

Comparação entre Pares

Variação de preço

Relay Therapeutics Inc Previsão

Preço-alvo

By TipRanks

385.33% parte superior

Previsão para 12 meses

Média 14.56 USD  385.33%

Máximo 23 USD

Mínimo 4 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Relay Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

9

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.88 / 3.285Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

170 / 382 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.